Breakthrough AI tools developed by Cambridge researchers can accurately predict cystic fibrosis progression, enabling personalized treatment plans tailored to individual patients' disease trajectories, competing health risks, and past cases, representing a major step towards precision healthcare.
Remarkable advancements in treatments, care, and newborn screening for cystic fibrosis have led to a soaring survival rate, with the median predicted age for CF patients born between 2017-2021 reaching 53 years, up from 38 years just a decade ago.
CAMP4 Therapeutics is pioneering a novel approach to treating genetic disorders by targeting regulatory RNA, which controls gene expression, using therapeutic molecules called antisense oligonucleotides to restore healthy protein levels, with lead candidates targeting urea cycle and seizure disorders.
In a groundbreaking development, the FDA has approved a key component of Precision Neuroscience's brain implant system, paving the way for paralyzed patients to potentially regain speech and movement through a cutting-edge brain-computer interface technology that rivals efforts by Neuralink, Synchron, and other prominent players.
Researchers developed a multimodal AI tool that combines language models and graph-based models to efficiently design new molecules with desired properties from natural language queries, outperforming existing methods and potentially automating the entire molecule design and synthesis process.
Pioneering a privacy-first approach, researchers are developing secure AI agents that prioritize data minimization, encryption, and rigorous auditing to gain user trust, drive adoption in regulated sectors, and simplify compliance with privacy regulations like HIPAA, GDPR, and CCPA.
In a groundbreaking collaboration, Ai2 and Google Cloud have jointly invested $20 million to establish the Cancer AI Alliance, leveraging AI's potential to accelerate cancer research through shared models and secure data analytics powered by Google's cloud infrastructure.
Scientists developed a starfish-shaped wearable device that leverages AI to precisely track heart health in real time with over 90% accuracy, even during movement, enabling comfortable long-term at-home monitoring with wireless charging and skin-friendly materials.
Clarify Clinics offers unproven treatments claiming to filter microplastics from blood, luring wealthy clients despite the lack of conclusive evidence on whether microplastics pose health risks, capitalizing on public concerns and willingness to pay for detox services.
Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.